Regression of HPV-Positive Tumors Treated With a New Listeria monocytogenes Vaccine
Open Access
- 1 January 2004
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 130 (1) , 92-97
- https://doi.org/10.1001/archotol.130.1.92
Abstract
Squamous cell carcinoma of the head and neck (HNSCC) remains a worldwide health problem. Recent estimates indicate more than 360 000 new cases of HNSCC worldwide annually, and more than 200 000 annual deaths.1 In the United States, an estimated 37 200 new cases will be diagnosed in 2003, with 11 000 deaths.2 Despite technological advances in surgery, radiation, and chemotherapy, 5-year survival rates remain less than 50% worldwide.1Keywords
This publication has 18 references indexed in Scilit:
- Genetically Engineered Tumor Cell Vaccine in a Head and Neck Cancer ModelThe Laryngoscope, 2003
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, 2002
- Two Listeria monocytogenes Vaccine Vectors That Express Different Molecular Forms of Human Papilloma Virus-16 (HPV-16) E7 Induce Qualitatively Different T Cell Immunity That Correlates with Their Ability to Induce Regression of Established Tumors Immortalized by HPV-16The Journal of Immunology, 2001
- Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2001
- Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck CancersJNCI Journal of the National Cancer Institute, 2000
- Human Papillomaviruses and Cervical Neoplasia: A Model for CarcinogenesisInternational Journal of Gynecological Pathology, 2000
- Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious diseaseImmunological Reviews, 1997
- A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumoursNature Medicine, 1995
- Bacterial Vaccine Vectors and Bacillus Calmette-GuerinClinical Infectious Diseases, 1995
- Immune Response to Human Papillomaviruses and the Prospects for Human Papillomavirus-Specific ImmunisationPublished by Springer Nature ,1994